Haematology
Polycythaemia / Myeloproliferative Neoplasm Workup
Distinguish PV / ET / MF — JAK2 mutation, secondary causes, symptom-directed therapy, thrombosis risk reduction.
Source: BSH 2018; WHO 2022
Step 1 of ~7
info
Recognise + Classify
Polycythaemia: Hb >185 g/L (M) / >165 g/L (F) OR haematocrit >0.52 (M) / >0.48 (F). Confirm true erythrocytosis (not pseudopolycythaemia from dehydration / smoking).
• Distinguish primary (PV) vs secondary (hypoxia, EPO-secreting tumour, COPD, OSA, smoking, high altitude, congenital).
Thrombocytosis: platelets >450 × 10⁹/L. Distinguish reactive (infection, inflammation, IDA, malignancy, splenectomy) from primary (ET, PV, CML, MF).
MPN suspicion: pruritus (especially aquagenic), erythromelalgia, splenomegaly, headache, paraesthesia, thrombosis (often unusual sites — splanchnic, cerebral, hepatic vein), gout (urate ↑).
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Eliglustat · Glucosylceramide synthase inhibitor (substrate reduction therapy)
- Icosapent Ethyl (Omega-3 — Cardiovascular Risk Reduction) · Omega-3 Fatty Acid (Purified EPA — Eicosapentaenoic Acid Ethyl Ester)
- Baricitinib 2–4mg (Atopic Dermatitis / Alopecia Areata) · JAK inhibitor (JAK1/JAK2) — systemic immunosuppressant
- Estradiol (HRT — Hormone Replacement Therapy) · Oestrogen Replacement Therapy
- Prednisolone (Oral — Nasal Polyp Reduction) · Systemic Corticosteroid
- Allopurinol · Xanthine Oxidase Inhibitor — Urate-lowering Therapy
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only. Always apply local guidelines and clinical judgement.